Baypoint Bio Licenses Ovarian, Breast Cancer Dx IP from MD Anderson | GenomeWeb

Baypoint Bio Licenses Ovarian, Breast Cancer Dx IP from MD Anderson

Mar 27, 2008

NEW YORK (GenomeWeb News) – Baypoint Biosystems said today it has licensed predictive biomarker intellectual property from the University of Texas MD Anderson Cancer Center in Houston.

The privately held company has obtained exclusive, worldwide rights to commercialize certain proteomics IP and clinical biomarkers for predicting therapeutic responses for certain ovarian and breast cancers.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

More Reproducible

Two new Reproducibility Project: Cancer Biology studies have largely reproduced the original findings, ScienceInsider reports.

To Catch the Swap

DNA fingerprinting could catch some sample mix-ups at pathology labs, the New York Times says.

Face of the Suspect

A Maryland police department has turned to DNA phenotyping to develop a suspect sketch, WJLA reports.

This Week in Cell

In Cell this week: DNA methylation and T cell exhaustion, longevity in C. elegans, and more.